Search Clinical Trials
Sponsor Condition of Interest |
---|
Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort
Independent Medical Alliance
Vaccine Adverse Reaction
Post Acute Covid-19 Vaccination Syndrome
The goal of this clinical trial is to evaluate whether metabolic modulation with a
combined nutraceutical product can improve symptoms and metabolic health in adults
diagnosed with post-acute Covid-19 vaccination syndrome (PACVS), a condition
characterized by persistent fatigue and exercise intoler1 expand
The goal of this clinical trial is to evaluate whether metabolic modulation with a combined nutraceutical product can improve symptoms and metabolic health in adults diagnosed with post-acute Covid-19 vaccination syndrome (PACVS), a condition characterized by persistent fatigue and exercise intolerance attributed to Covid-19 vaccination and confirmed by laboratory testing. The main questions it aims to answer are: Does the combined nutraceutical intervention improve quality of life (measured by the PAC-19QoL questionnaire) in PACVS patients? Does the intervention improve metabolic, inflammatory, and functional biomarkers (e.g., HbA1c, blood lactate, CRP, spike protein levels, heart rate variability, 6-minute walk distance)? Researchers will compare the intervention group (receiving the ViTAL SCAN nutraceutical) to a placebo group (receiving rice protein powder with vitamin C) to determine if the intervention leads to greater improvements in symptoms and biomarker profiles. Participants will: Take the assigned supplement daily for 3 months (ViTAL SCAN or placebo) Attend clinic visits for blood and urine sampling, physical performance tests (6-minute walk test), and heart rate monitoring Complete quality of life and health behavior questionnaires Undergo measurements of metabolic and inflammatory markers (HbA1c, lactate, CRP, spike protein) Record supplement intake This study is currently pending IRB approval and aims to enroll 100 adults with PACVS for a randomized, placebo-controlled trial. Type: Interventional Start Date: Sep 2025 |
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID1
CyanVac LLC
COVID-19
The purpose of this trial is to assess the safety and relative efficacy of CVXGA
(CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA;
2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of
symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. T1 expand
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 10016 healthy participants. Type: Interventional Start Date: Dec 2024 |
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
GlaxoSmithKline
COVID-19
This study will evaluate the reactogenicity, safety, and immune response of Flu
Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will
target multiple strains of the flu virus, while the COVID-19 part will focus on the spike
protein of the SARS-CoV-2 virus. Both part1 expand
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants. Type: Interventional Start Date: Nov 2024 |
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With C1
Pfizer
COVID-19 SARS-CoV-2 Infection
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in
adults and adolescents with COVID-19 who do not need to be in the hospital but who are at
high risk for progression to severe disease. Eligible participants will be randomly
assigned (by chance) to receive ibuzatr1 expand
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months. Type: Interventional Start Date: Dec 2024 |
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
Kanecia Obie Zimmerman
Long COVID
Long Covid19
Long Covid-19
This study is a platform protocol designed to be flexible so that it is suitable for a
wide range of settings within health care systems and in community settings where it can
be integrated into COVID-19 programs and subsequent treatment plans.
This protocol is a prospective, multi-center, multi-a1 expand
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs. Type: Interventional Start Date: Mar 2024 |
Community Care Intervention to Decrease COVID-19 Vaccination Inequities
RAND
COVID-19 Vaccination
The purpose of this study is to find out if a community health workers (CHW) intervention
conducted in Federally Qualified Health Centers (FQHCs) can increase the number of adults
with chronic illnesses who are up-to-date with their COVID-19 and influenza vaccines. expand
The purpose of this study is to find out if a community health workers (CHW) intervention conducted in Federally Qualified Health Centers (FQHCs) can increase the number of adults with chronic illnesses who are up-to-date with their COVID-19 and influenza vaccines. Type: Interventional Start Date: Sep 2023 |
Do EEG and Neurocognitive Assessments Correlate With COVID Brainfog Symptoms?
Texas Tech University Health Sciences Center, El Paso
COVID-19
Since the neurologic symptoms of some COVID patients ('brain fog') resemble those of
patients with concussion, the aim of this study is to identify EEG and cognitive function
changes in COVID patients. We will use the FDA cleared BrainScope medical device in
conjunction with standard neurocognitive1 expand
Since the neurologic symptoms of some COVID patients ('brain fog') resemble those of patients with concussion, the aim of this study is to identify EEG and cognitive function changes in COVID patients. We will use the FDA cleared BrainScope medical device in conjunction with standard neurocognitive tests to identify correlations with electrical biomarkers and to potentially identify new, unique patterns of altered brain electrical activity associated with COVID-19 infection. A baseline assessment will be performed shortly after hospital presentation and then a second evaluation will be performed 45-60 days post hospital discharge to reassess clinical status, brain electrical biomarkers and neurocognitive performance. The goal will be to develop an objective measurement of brain function/dysfunction associated with COVID-19 infection which might be employed in future studies of treatments for COVID-19 brain fog and to aid in tracking recovery. Type: Observational Start Date: Apr 2022 |
Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)
Massachusetts General Hospital
Dysexecutive Syndrome
Post-Acute Sequelae of COVID-19
The main goal of this study is to improve dysexecutive symptoms (e.g., sustained
attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19
(PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive
method that uses low intensity electric curren1 expand
The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp. Type: Interventional Start Date: Jun 2022 |
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treate1
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis (RMS)
This study evaluated if relapsing multiple sclerosis (MS) participants treated with
ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate
immune response to the COVID-19 mRNA vaccine compared to participants on an interferon or
glatiramer acetate. expand
This study evaluated if relapsing multiple sclerosis (MS) participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate immune response to the COVID-19 mRNA vaccine compared to participants on an interferon or glatiramer acetate. Type: Interventional Start Date: Jun 2021 |
Natural History Study of COVID-19 Using Digital Wearables
National Institute on Minority Health and Health Disparities (NIMHD)
COVID-19 Virus Disease
Background:
People with COVID-19 have varying degrees of illness. It can range from no or mild
symptoms to critical illness and death. Some people with COVID-19 have long-term effects
regardless of the severity of their disease initially. Researchers want to learn more to
see if they can better pr1 expand
Background: People with COVID-19 have varying degrees of illness. It can range from no or mild symptoms to critical illness and death. Some people with COVID-19 have long-term effects regardless of the severity of their disease initially. Researchers want to learn more to see if they can better predict where a person may fall on the illness spectrum. Objective: To follow and record symptoms of COVID-19 to see how it progresses in people and why some people stay sick longer than others. Eligibility: People ages 18-65 who received a COVID-19 positive test result in the 72 hours before their enrollment in the study. Design: Participants will complete a 30-minute baseline survey. They will answer questions about themselves and their health. Participants will get a digital wristband and temperature sensor in the mail. They will get instructions on how to set up and wear the devices. They will download a mobile application on their phone. The app will collect data from the devices. Participants will wear the wristband and sensor every day for the first month. Then they will wear the devices for a total of 40 days over the next 5 months. On the days they wear the devices, they will answer a 2-question health survey via the app. Participants will answer a 20-minute online survey about their health every 30 days. If participants are hospitalized, a family member or close friend will be asked to complete a brief 7-minute online survey about their hospital stay and treatment. Participants will be sent alerts and reminders throughout the study. Participation will last for 6 months. Type: Observational Start Date: Oct 2021 |
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americ1
National Human Genome Research Institute (NHGRI)
Heart Disease
Background:
The COVID-19 pandemic infected and killed African Americans at higher rates than other
Americans. Researchers want to understand why.
Objective:
This natural history study will look at how genetic, environmental, and social factors
may predict or affect COVID-19 in African Americans.1 expand
Background: The COVID-19 pandemic infected and killed African Americans at higher rates than other Americans. Researchers want to understand why. Objective: This natural history study will look at how genetic, environmental, and social factors may predict or affect COVID-19 in African Americans. Information from this study will be combined with data from the GENE-FORECAST study. Eligibility: African Americans who were previously enrolled in GENE-FORECAST. Design: The study includes a telephone interview and 1 visit to the NIH clinic. Participants may engage in either one or both of these activities. The telephone interview will last 20 minutes. Participants will talk about their experiences during the COVID-19 pandemic. The clinic visit will last up to 4 hours. Participants will have a physical exam. They will have blood and urine tests. They will be tested for COVID-19. A long swab will be inserted into a nostril to get a fluid sample from the back of the nose. They will have noninvasive tests of their blood vessels. One device used is a pen-like probe placed lightly on the wrist. Another is a rubber sleeve placed around a finger while a blood pressure cuff is used on the arm. Participants will have a test to measure the electrical activity in their heart. Stickers attached to wires will be placed on their chest, arms, and legs. Participants will answer more questions about COVID-19. They will talk about their health behavior. They will talk about their family's health and the neighborhood they live in. Other questions will ask how they feel, live, work, and play. Type: Observational Start Date: Feb 2023 |
An Observational Study of Neurologic Function After COVID-19 Infection
National Institute of Neurological Disorders and Stroke (NINDS)
COVID-19
Background:
COVID-19 is an infection caused by a coronavirus. It can affect different parts of the
body. For most people, it causes fevers or trouble breathing. Some people can have
symptoms long after they recover. Researchers want to learn if there are signs of changes
in the nervous system that1 expand
Background: COVID-19 is an infection caused by a coronavirus. It can affect different parts of the body. For most people, it causes fevers or trouble breathing. Some people can have symptoms long after they recover. Researchers want to learn if there are signs of changes in the nervous system that may be related to COVID-19. Objective: To test the nervous system (the brain and nerves) in people who have had COVID-19 yet still have certain symptoms even after recovering. Eligibility: People age 18 and older who had COVID-19 and still have neurologic symptoms after they recovered from the initial infection. Design: Participants will be screened with a medical record review. Participants will have a neurological exam. They will complete pen-and-paper tests of their memory and thinking. They will complete a smell test with 'scratch-and-sniff' booklets. They will give blood samples. Participants will have magnetic resonance imaging (MRI) of the brain. Soft padding or a coil will be placed around their head. They will lie on a table that slides in and out of the MRI scanner. They will get a contrast dye through an intravenous (IV) catheter. Participants blood pressure, blood flow, skin temperature, sweating, and breathing will be monitored. Participants will have an electrocardiogram to measure heart function. Participants will blow into a mouthpiece for several seconds. Participants will lie on a table that has a motor. The motor tilts the table. Participants will have blood drawn through an IV as the table tilts. Participants will have a lumbar puncture. A small needle will be inserted into the spinal canal to obtain fluid. Participants may repeat some tests 8 weeks to 1 year later. Type: Observational Start Date: Oct 2020 |
Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine
Pfizer
COVID-19
This study is a retrospective case control analysis on the real-world effectiveness of
the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic
SARS-CoV-2 infection among CVS MinuteClinic patients testing for SARS-CoV-2, across
different age groups, during periods of various1 expand
This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing for SARS-CoV-2, across different age groups, during periods of various variant circulation, and by months since receipt of vaccine dose. Type: Observational Start Date: Nov 2024 |
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic an1
Wes Ely
Long COVID
Sars-CoV-2 Infection
Coronavirus Infections
COVID-19
The overarching goal of this study is to determine if baricitinib, as compared to
placebo, will improve neurocognitive function, along with measures of physical function,
quality of life, post-exertional malaise, effect of breathlessness on daily activities,
post-COVID-19 symptom burden, and biomar1 expand
The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID. Type: Interventional Start Date: Oct 2024 |
SMILE: Clinical Trial to Evaluate Mindfulness as Intervention for Racial and Ethnic Populations Dur1
University of North Carolina, Chapel Hill
Anxiety
COVID-19 Pandemic
The goal of this clinical trial is to evaluate the SMILE app, a Digital Health Platform
(DHP), that will deliver a mindfulness intervention, designed to mitigate COVID-19
related stress. Additionally, the SMILE app will remotely collect self-reported
psychological and physiological metrics of menta1 expand
The goal of this clinical trial is to evaluate the SMILE app, a Digital Health Platform (DHP), that will deliver a mindfulness intervention, designed to mitigate COVID-19 related stress. Additionally, the SMILE app will remotely collect self-reported psychological and physiological metrics of mental health and autonomic regulation. Study participants are adults who self-identify as African American, Black and/or Latino, and who have clinically significant levels of anxiety. The study aims are: - Aim 1: Establish the effectiveness and durability of an 8-week Mindfulness DHP intervention. The investigators will focus on two constructs important to mental health and hypothesize that: A) Anxiety, self-report stress and quality-of-life measures will significantly improve when comparing: A.1) Pre-to-post intervention, and; A.2) Control vs. intervention groups over 8 weeks and at 1-month follow-up. B) Arousal, autonomic indices of HRV (reflecting parasympathetic activation) will significantly improve, when comparing: B.1) Pre-to-post intervention, and; B.2) Control vs. intervention groups over 8 weeks and at 1-month follow-up. - Aim 2: Establish the sustainability of two Mindfulness DHP interventions utilizing retention, usage (frequency), and participant satisfaction. - Aim 3: Examine associations between COVID-19 related stress, mental health outcomes, and HRV. Examine the extent to which COVID-19 related stress and mental health symptoms are linked to HRV at baseline and how that relationship changes over time. Participants will be assigned to 1 of 3 arms of the study: MTIA intervention, MAPP intervention, or wait-list control. All participants will be mailed a device with the SMILE app installed, and the equipment for recording cardiac data in the home. All participants will complete the baseline psychometrics measures and physiological stress test using the instructions provided on the SMILE app. Those assigned to the MTIA or MAPP intervention groups will then participate in their assigned intervention over the subsequent 8 weeks. During these 8 weeks, psychometric and physiological data will be completed biweekly for all participants. 3 months following the initial baseline, all participants will complete a final psychometric/physiological evaluation. Type: Interventional Start Date: May 2024 |
Vale+Tú Salud: Corner-Based Randomized Trial to Test a Latino Day Laborer Program Adapted to Preven1
The University of Texas Health Science Center, Houston
COVID-19
The purpose of this study is to assess the extent to which LDL report increased adherence
with COVID 19 mitigation practices 1 month post intervention. expand
The purpose of this study is to assess the extent to which LDL report increased adherence with COVID 19 mitigation practices 1 month post intervention. Type: Interventional Start Date: Nov 2023 |
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
Pfizer
SARS-CoV-2
COVID-19
Post-Acute COVID-19 Syndrome
This study aims to use vaccination information from state vaccine registries linked with
HealthVerity insurance claims for the following:
- to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID
conditions.
- to understand characteristics of patients who are r1 expand
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: - to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions. - to understand characteristics of patients who are receiving COVID-19 vaccines. All patients whose information is kept unidentified in the HealthVerity database are eligible to be included for both aims of this study. Type: Observational Start Date: Oct 2023 |
A Nasal Treatment for COVID-19
Indiana University
COVID-19
The goal of this study is to test an investigational new inhaled medication called
Optate. expand
The goal of this study is to test an investigational new inhaled medication called Optate. Type: Interventional Start Date: Jun 2023 |
Fatigability in Long COVID-19
VA Office of Research and Development
Long COVID
The overall goal of this project is to advance the understanding of underlying mechanisms
impacting performance fatigability and perceived fatigability in Veterans with
post-COVID-19 fatigue and explore the safety and feasibility of a home-based
"minimal-dose" resistance exercise program in this po1 expand
The overall goal of this project is to advance the understanding of underlying mechanisms impacting performance fatigability and perceived fatigability in Veterans with post-COVID-19 fatigue and explore the safety and feasibility of a home-based "minimal-dose" resistance exercise program in this population. The central hypothesis is that declines in force capacity, skeletal muscle oxygen extraction, and affective responses to physical activity offer potential mechanisms through which fatigability is increased in Veterans with post-COVID-19 fatigue. Moreover, home-based resistance exercise delivered remotely may provide a safe and feasibility treatment option for targeting neuromuscular and neurobehavioral factors influencing fatigability severity in this population. Type: Interventional Start Date: Jul 2023 |
Back to ECE Safely With SAGE: Reducing COVID-19 Transmission in Hispanic and Low-income Preschoolers
Arizona State University
COVID-19 Testing
Children, Preschool
Parents
Child Development
Self-Control
This study aims to get children safely back to school by (1) Child and Family Testing,
(2) ECE Personnel Testing, and (3) Outdoor Learning via Garden Education. expand
This study aims to get children safely back to school by (1) Child and Family Testing, (2) ECE Personnel Testing, and (3) Outdoor Learning via Garden Education. Type: Interventional Start Date: Nov 2021 |
Study of Varespladib in Patients Hospitalized With Severe COVID-19
Ophirex, Inc.
Coronavirus Disease 2019
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2
study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in
addition to standard of care, in patients hospitalized with severe COVID-19 caused by
SARS-CoV-2. expand
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients hospitalized with severe COVID-19 caused by SARS-CoV-2. Type: Interventional Start Date: Jun 2021 |
Prophylaxis and Treatment of COVID-19
Henry M. Jackson Foundation for the Advancement of Military Medicine
COVID-19
Acute Respiratory Infection
An observation study evaluating physiologic responses and host biomarker expression
patterns in early SARS-CoV-2 and acute respiratory infections (ARI) and among their close
contacts. expand
An observation study evaluating physiologic responses and host biomarker expression patterns in early SARS-CoV-2 and acute respiratory infections (ARI) and among their close contacts. Type: Observational Start Date: Jun 2021 |
Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With1
Thomas Jefferson University
Covid19
This clinical trial will study the safety and efficacy of COVID-19-specific T cells when
given as treatment to adult patients (age ≥ 18 years) with a COVID-19 infection. This
immunologic treatment is aimed at patients, who are at high risk of progression due to
their advanced age, or other underlyi1 expand
This clinical trial will study the safety and efficacy of COVID-19-specific T cells when given as treatment to adult patients (age ≥ 18 years) with a COVID-19 infection. This immunologic treatment is aimed at patients, who are at high risk of progression due to their advanced age, or other underlying health conditions. The outcomes of patients receiving the T cells (Arm A) will be compared to patients treated with standard of care (Arm B). Type: Interventional Start Date: Sep 2021 |
A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
Janssen Vaccines & Prevention B.V.
COVID-19 Prevention
The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S
administered intramuscularly (IM) as a 1-dose schedule at the standard dose level in
adult participants during the second and/or third trimester of pregnancy and
(potentially) post-partum; to assess the humoral immu1 expand
The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule at the standard dose level in adult participants during the second and/or third trimester of pregnancy and (potentially) post-partum; to assess the humoral immune response in peripheral blood of adult participants to Ad26.COV2.S administered IM as a 1-dose schedule during the second and/or third trimester of pregnancy, 28 days after vaccination. Type: Interventional Start Date: Aug 2021 |
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
M.D. Anderson Cancer Center
COVID-19 Infection
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
The study investigates how the COVID-19 pandemic has impacted the psychological,
financial, physical, and social well-being of adolescent and young adult (AYA) cancer
patients and survivors. AYA cancer survivors have inferior long-term survival compared to
the general population, and the negative i1 expand
The study investigates how the COVID-19 pandemic has impacted the psychological, financial, physical, and social well-being of adolescent and young adult (AYA) cancer patients and survivors. AYA cancer survivors have inferior long-term survival compared to the general population, and the negative impact of the global COVID-19 pandemic may be even higher in this vulnerable group. The information gained from this study may provide an opportunity to determine the self-reported COVID-19 specific psychological distress in AYA cancer survivors, and may lead to the development of a targeted intervention to improve physical and psychosocial health for AYA cancer patients and survivors. Type: Observational Start Date: Jul 2020 |
- Previous
- Next